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1High blood pressure is a leading risk factor for stroke and coronary heart disease and subsequent disability inter-
nationally.1 A 10 mm Hg reduction in blood pressure (BP) is 
estimated to lead to a 41% reduction in stroke and a 22% re-
duction in coronary heart disease.2 Lowering blood pressure 
with pharmacological and nonpharmacological methods is 
both clinically and cost-effective.3 Ensuring that the correct 
people receive such treatment maximizes benefit whilst re-
ducing adverse effects.
The 2011 National Institute for Health and Care Excellence 
(NICE) Hypertension Guideline introduced, for the first time 
in the United Kingdom, recommendations for the diagnosis 
of hypertension that included the use of out-of-office meas-
urement for confirmation of an initially raised clinic blood 
pressure.3 The routine use of out-of-office monitoring in 
the diagnosis of hypertension is now also recommended in 
Canada, the United States, Japan, and Europe.4–7 This change 
was in response to concerns that using clinic blood pressure 
may result in ≈25% of individuals being misclassified due 
to white coat hypertension, leading to potential unnecessary 
costs and adverse events.8 Furthermore, the use of ambulatory 
blood pressure monitoring (ABPM), and to a lesser extent 
home blood pressure monitoring, reduces this misclassifica-
tion8 and is cost-effective compared with clinic monitoring.9
However, these changes were not without controversy. It 
was suggested that implementation would result in an additional 
5000 cardiovascular events each year in England and Wales.10 
Others argued that the use of ambulatory monitoring in the diag-
nosis of hypertension was inappropriate given that most evidence 
related to the treatment of hypertension is based on clinic blood 
pressure readings.11 Conversely, at a time of increasing workload 
and decreasing funding in UK General Practice,12,13 the changes 
were predicted to reduce clinical workload due to a reduction in 
the unnecessary treatment of white coat hypertension.3
Sufficient time has now passed since the introduction of the 
NICE 2011 guideline to assess its impact on the management 
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of hypertension and outcomes. We aimed to use data from the 
Clinical Practice Research Datalink (CPRD), a large data-
base of routine electronic health records from primary care in 
England, to examine trends in the incidence of hypertension, 
use of out-of-office blood pressure monitoring, and cardiovas-
cular morbidity and mortality from 2006 to 2017. We further 
aimed to test whether the introduction of the revised NICE 
Hypertension guideline in 2011 was associated with a change 
in these trends.
Methods
The data used in this study were obtained under licence from the 
Medicines and Healthcare products Regulatory Agency, which does 
not permit data sharing. Equivalent data may be obtained subject to 
the terms outlined here: https://www.cprd.com/research-applications.
Study Design
This was a retrospective cohort study of adults (aged 18 years and 
over) registered at general practices contributing to the CPRD be-
tween April 1, 2006 and March 31, 2017. The CPRD is a research 
database of routinely collected primary care records, drawn from 
over 600 general practices and 11 million patients who are represen-
tative of the UK population.14 Data from CPRD were linked to inpa-
tient Hospital Episodes Statistics (hospital data), Office for National 
Statistics mortality register data, and Index of Multiple Deprivation 
data (describing patient socio-economic status). Patients were eli-
gible for inclusion if their records met basic quality measures, such 
as nontemporary registration and practice registration occurring after 
birth (termed acceptable records by CPRD) and were eligible for data 
linkage (which meant patients registered to English practices only). 
Furthermore, patients had to be registered at practices with contin-
uous data reporting during the study period (termed up-to-standard by 
CPRD). Patients were excluded if they had a history of hypertension 
before study entry, because the change in guidance was limited to the 
use of out-of-office monitoring for diagnosis alone. We hypothesized 
that the change in guidance would, therefore, have a limited impact 
on those with a long-standing diagnosis of hypertension. See the ex-
tended methods in the online-only Data Supplement for further details 
and sample size calculations.15,16 The study protocol was approved by 
the Independent Scientific Advisory Committee to CPRD (protocol 
number 17_239R) and was made available during peer review.
Outcomes
The primary outcome was incidence of hypertension (defined as the 
presence of a first diagnostic code in the primary care record; Table 
S1 in the online-only Data Supplement). We considered the incidence 
of treated hypertension (presence of a clinical diagnostic code with 
antihypertensive treatment within 30 days) and untreated hyperten-
sion (presence of a diagnostic code without treatment). In sensitivity 
analyses, incidence of hypertension was defined according to (1) a 
clinical code for hypertension with or without a subsequent record 
of antihypertensive treatment or (2) 2 raised BP readings (clinic BP 
≥140/90 mm Hg or out-of-office BP ≥135/85 mm Hg) followed by a 
record of antihypertensive treatment.
We studied the following prespecified secondary outcomes: rate 
of new prescriptions of antihypertensive medication, rate of blood 
pressure monitoring (clinic, ambulatory, home, and overall), inci-
dence of (major) cardiovascular events (cardiovascular death, myo-
cardial infarction, or stroke), cardiovascular mortality, and all-cause 
mortality. The specific definitions for each outcome are given in the 
extended methods in the online-only Data Supplement.
Statistical Analysis
For each outcome, rates per 100 person-years were calculated for 
each age-sex stratum (male/female and 18–24, 25–44, 45–54, 55–64, 
65–74, 75–84, and 85+) in each month. In primary analyses, rates 
were standardized to the English National Population standard in 
2015 to account for changes in the age-sex distribution over time. In 
sensitivity analyses, rates were standardized according to the age, sex 
and socio-economic status (Index of Multiple Deprivation) of the co-
hort in March 2017. We performed prespecified subgroup analysis in 
those who had/had not developed hypertension before the beginning 
of each month from April 2007 onwards (allowing 1 year for incident 
hypertension cases to develop).
Standardized rates were examined using interrupted time series a-
nalysis.17 Interrupted time series analysis is appropriate for examining 
the impact of health interventions and policies at a population level, 
when such interventions have been implemented at a clearly defined 
point in time.17 We assessed whether the introduction of the NICE 
Hypertension guideline in 2011 was associated with a step change 
in rates or a change in trend, by interrupting the time series between 
April 1, 2011 and March 31, 2012. Since patients could enter and 
exit the cohort at varying time points across the entire study period, 
monthly rates were calculated using data from varying person-years 
of observation. To account for this, analytical weights (equal to the 
person-years of observation) were used to estimate weighted inter-
rupted time series models. We investigated the presence of autocorre-
lation and the influence of seasonality by including lag terms (up to 
order 12) in sensitivity analyses.
In post hoc analyses, we examined the incidence of a control con-
dition, asthma. Asthma (like hypertension) is diagnosed, monitored, 
and managed in primary care but (unlike hypertension) should not be 
causally related to changes in hypertension guidelines. Inclusion of a 
negative control helps ensure that any observed changes in outcomes 
are plausibly related to the exposure of interest rather than secular 
trends.18 We also examined the incidence of hypertension and major 
cardiovascular events in practices with high rates of reported out-of-
office monitoring (top 20% between 2006 and 2017) to assess the 
possible impact of coding differences.
Data on age and sex were complete. Patients with missing dep-
rivation data (0.08%) were assumed to be in the middle quintile of 
deprivation. For all outcomes, absence of a relevant diagnostic or 
medication code was assumed to reflect absence of disease/treatment. 
All analysis was conducted using Stata version 14.19 Further details of 
data cleaning and analysis are given in the extended methods section 
in the online-only Data Supplement. S.L. Lay-Flurrie had access to 
the full CPRD database and conducted all data cleaning and analysis. 
Linked data was provided directly by CPRD.
Results
In total 3 937 191 patients from the January 2018 CPRD data-
base were eligible for inclusion in the study cohort (Figure 1). 
Mean age at study entry was 39.7 years (SD=17.3), and 49.0% 
were male. There were 19 088 414 person-years of follow-up 
in total, and median follow-up was 4.2 years (interquartile 
range, 1.6–8.0). The characteristics of the cohort at study 
entry are given in Table 1.
Incidence of Hypertension
In total, 236 554 (6.0%) patients developed incident hyperten-
sion during the study period (crude incidence rate of 1.31 per 
100 person-years; Table S2). The age and sex standardized in-
cidence of hypertension decreased over the study period from 
2.10 per 100 person-years (95% CI, 1.96–2.25) in April 2006 
to 1.39 per 100 person-years (95% CI, 1.28–1.49) in March 
2017 (Figure 2 and Table 2). The year 2011, when the revised 
NICE hypertension guideline was introduced, was not associ-
ated with a significant change in the incident rate level (change 
in rate =0.01 [95 % CI, −0.18–0.20]). It was, however, associ-
ated with a reduction in the yearly downward trend (change in 
trend =0.093 [95% CI, 0.035–0.151]), but a similar reduction 
was observed in the negative control condition, asthma (Figure 
S1). The majority of incident hypertension cases were treated, 
and the same pattern in incidence was observed in treated and 
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untreated groups (Table S3). When considering a more sensi-
tive definition of hypertension, the incidence rate was higher 
but patterns in adjusted rates were similar (Table S4).
Blood Pressure Monitoring
Patients were recorded as having home and ambulatory moni-
toring on 39 260 and 98 071 occasions, respectively (crude rate 
of 0.2 and 0.5 per 100 person-years, respectively). In compar-
ison, patients had recorded clinic blood pressure on 14 717 205 
occasions (crude rate of 77.1 per 100 person-years). The change 
in guidance in 2011 was associated with a significant change 
in the age and sex standardized rates of home and ABPM and 
a significant change in the trend for home monitoring (Table 
S5 and Figure 3). The 2011 guidance was associated with a 
change in a downwards trend of clinic BP monitoring but not 
a change in the level. In those with a diagnosis of hyperten-
sion, the proportion who had a record of home or ambulatory 
BP monitoring before their diagnosis increased from 3.7% for 
those diagnosed in 2006/2007 to 25.6% in 2016/2017.
Cardiovascular Morbidity, Mortality, and All-Cause 
Mortality
After excluding 63 623 patients with a history of major car-
diovascular disease (myocardial infarction or stroke) before 
study entry, 66 785 patients (1.7%) had an incident MI or 
stroke during the study period (crude incidence rate of 0.36 
per 100 person-years). The standardized incidence rate of car-
diovascular disease was unchanged across the study period 
(Figure 4). The introduction of new NICE guidance in 2011 
was not associated with changes in the incidence rate or trend 
in CVD (Table S6). Rates of any CVD and all-cause mortality 
were unchanged across the study period, but there were small 
(borderline significant) changes in trend for rates of major 
CVD mortality and any CVD mortality (5–8/100 000 patient 
years per year change).
New Antihypertensive Medication Use
In total 11% of patients (399008 of 3 643 319) received anti-
hypertensive medications for the first time during the study 
period (crude incidence rate of 2.5 per 100 person-years). The 
age-sex standardized rate of new antihypertensive medication 
use decreased during the study period (Figure S2 and Table 
S7). The change in guidance in 2011 was not associated with 
a change in rate (change in rate =−0.105 [95% CI, −0.406 to 
0.196]) but was associated with a flattening of the previously 
downward trend (change in trend =0.096 [95% CI, 0.007–
0.185]). There was no clear change in the pattern of prescrib-
ing of at least one medication in each class (Figure S3).
Sensitivity and Post Hoc Analyses
There was some evidence of seasonality in rates but account-
ing for this produced similar results to primary analyses. An 
exception was for our broad definition of (any) CVD events, 
where the change in guidance was associated with a small de-
crease in the incidence rate level and a flattening trend (data 
not shown). Results for incidence of hypertension were also 
similar when standardizing according to age, sex, and depriva-
tion in the final month of analysis (data not shown).
Results stratified by hypertensive status are given in 
Figures S4 through S8 and Table S8. Absolute rates of BP 
monitoring, incident CVD, and incident antihypertensive 
treatment were higher in patients with hypertension com-
pared with those without. The change in guidance in 2011 
was associated with larger absolute changes in the rate of 
ambulatory blood pressure monitoring and home monitor-
ing in hypertensive compared with normotensive groups but 
Figure 1. Study flow-chart. Note: Records are termed acceptable if they 
meet basic quality measures. Practices reporting data continuously during 
the study period are termed up-to-standard. CPRD indicates Clinical 
Practice Research Datalink; HES, Hospital Episode Statistics; and ONS, 
Office for National Statistics.
Table 1. Baseline Study Characteristics
Variable N=3 937 191
Age, y, median (interquartile range) 36 (26–50)
Male, % 49.0%
Follow-up, y, median 4.2
Ethnicity, %
  White 47.6
  Nonwhite 9.0
  Unknown 43.4
 Prior major CVD (MI or stroke, %) 1.6
 Prior CVD (any, %) 4.9
Index of multiple deprivation (measured across England, quintile)
  1 (least deprived, %) 22.1%
  2 22.1%
  3 19.9%
  4 20.6%
  5 (most deprived) 15.2%
  Unknown 0.1%
CVD indicates cardiovascular disease; and MI, myocardial infarction.
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similar relative changes. Yearly trends in the rate of ambu-
latory and home monitoring remained largely flat across the 
study period in normotensive patients. Conversely, in hyper-
tensive patients, trends in the rate of ambulatory and home 
BP monitoring changed significantly (from decreasing to flat 
and flat to increasing respectively). There was little change 
in the rate of office BP monitoring which continued its 
downward trend. For incident major CVD events (myocar-
dial infarction and stroke), rates remained unchanged in both 
hypertensive and normotensive groups. Finally, the change 
in guidance was associated with a large increase in the rate 
of new antihypertensive treatment in patients with hyperten-
sion but no change in patients without.
In practices with high rates of recorded out-of-office moni-
toring, the incidence of hypertension and major CVD events 
were similar to that observed in all practices (Figures S9 and 
S10). In 2011, there was no change in the incidence rate level of 
hypertension (change in rate =0.06 [95% CI, −0.16–0.27) but 
a leveling off of downward trend (change in yearly trend =0.09 
[95% CI, 0.02–0.15). There was no change in the level or trend 
for incidence of major CVD events (change in rate =−0.001 
[95% CI, −0.056–0.055]; change in yearly trend =0.010 [95% 
CI, −0.009–0.030]). Although these practices were selected for 
having high rates of out-of-office monitoring across the study 
period, a large increase in the use of out-of-office monitoring 
was also observed in this subgroup after 2011 (Figure S11).
Discussion
The introduction of the NICE Hypertension guideline in 
England in 2011 was associated with a leveling out of down-
ward trends in the incidence of diagnosed hypertension, 
although this may not be causal. In 2011, there was a step-
change in the rate of ambulatory and home BP monitoring, 
in those with and without hypertension, suggesting changes 
in BP measurement occurred for diagnosis and monitoring. 
However, changes were modest in absolute terms imply-
ing perhaps issues with guideline implementation or coding 
of monitoring. By 2017, around a quarter of new diagnoses 
were accompanied by evidence of out-of-office monitoring. 
Contrary to previous predictions,10 there was little or no change 
in the incidence of cardiovascular morbidity or mortality.
Strengths and Limitations
This was a large scale analysis of high-quality data representa-
tive of the UK population.14 The majority of excluded patients 
Figure 2. Age and sex standardized incident rate of hypertension (per 100 person-years) between April 2006 and March 2017, with interruption between 
April 2011 and March 2012.
Table 2. Results From Interrupted Time Series Analysis of Age and Sex 
Standardized Rates of Incident Hypertension Between April 2006 and March 
2017, With Interruption Between April 2011 and March 2012
Model Parameter
Estimate  
(per 100 person-years) 95% CI
Initial rate (April 2006) 2.103 1.959 2.246
Initial trend per year (April 
2006–March 2011)
−0.108 −0.153 −0.062
Predicted rate (April 2012) 1.447 1.286 1.608
Post-intervention rate (April 
2012)
1.458 1.36 1.555
Post-intervention trend per 
year (April 2012–March 
2017)
−0.014 −0.051 0.022
Change in rate 0.011 −0.177 0.199
Change in trend 0.093 0.035 0.151
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were those not registered at contributing practices or within 
the study age range during the study period (Figure 1). Other 
exclusions were those not eligible for data linkage (largely 
those registered at practices outside of England) and those 
without acceptable records for research (primarily those reg-
istered as temporary patients with unknown follow-up status). 
The age and sex profiles of those included/ not on this basis 
were similar (data not shown),and since all people resident in 
Figure 3. Age and sex standardized rate of blood pressure monitoring (per 100 person-years) by month from April 2006 to March 2017 with interruption 
between April 2011 and March 2012.
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the England are entitled to access national health services, we 
are confident that selection bias was limited. Our use of stan-
dardized rates further increases the applicability of the results 
to wider populations, even in the presence of differences in 
age and sex demographics.
We used diagnostic codes to define hypertension diagno-
ses which may have led to an underestimate of incidence.20 
However, trends over time were similar when considering a 
broader definition, and patterns mirrored those observed in 
the United Kingdom for resistant hypertension.21 We could 
not use data from the Myocardial Infarction National Audit 
Project (a comprehensive register of patients experienc-
ing MI) to ascertain fully validated MI outcomes. However, 
CPRD data is the most complete single source of information 
and when combined with hospital data as here, 92% of MI 
cases are identified.22 The effect of any under ascertainment 
of events in our composite outcomes is, therefore, likely to be 
limited. Reassuringly, we observed a decline in CVD-related 
mortality consistent with national statistics.23
Interrupted time series analysis cannot establish cau-
sality, as demonstrated by our finding that the incidence 
rate of asthma changed in 2011, which cannot plausibly be 
attributed to the hypertension guideline change. Our results 
may be influenced by coincidental factors including increases 
in general practitioner workload between 2007 and 201412 
without equivalent increases in staffing levels,24 which may 
have reduced access for patients, resulting in fewer diagnoses. 
Conversely, mortality rates declined and healthcare spend-
ing increased in the years before 2011, but both have since 
leveled off.25 Population-level improvements in health in the 
early years of our study may, therefore, not have been main-
tained. Nevertheless, our results were similar across analyses 
of CVD events and mortality regardless of the definition of 
CVD. Results for our primary outcome were also unaffected 
when adjusting for deprivation in addition to age and sex or in 
practices with greater use of out-of-office monitoring.
We chose to study major cardiovascular outcomes and 
mortality, to reflect the overall goal of BP lowering and pow-
ered the study to detect small changes in incidence levels and 
trends in the presence of autocorrelation. Previous studies in 
UK databases have been able to detect differences in CVD 
event and mortality rates in smaller numbers of patients with 
less follow-up.26 We are confident we could have detected 
changes in these outcomes in the medium term if they truly 
existed but cannot exclude the possibility that the effects of 
guideline change may only manifest in the longer term. Such 
lagged effects could be studied once further time has elapsed.
Guideline changes may have affected GP practices differ-
ently, depending on uptake. Models including random effects 
for GP practice were infeasible due to the large volumes of data 
in this study. This necessitated the use of yearly aggregate data 
in each age-gender strata and weighted analysis, but contempo-
rary statistical software cannot implement random effects mod-
els with analytical weights. However, we were able to repeat 
analyses in practices with high levels of recorded out-of-office 
monitoring, and results in this subgroup were similar. Our use 
of age and sex as standardization variables meant we were un-
able to study patterns stratified by age or sex. Review evidence 
suggests that gender, in particular, is associated with the pres-
ence of masked and white coat hypertension,27 and therefore, 
the change in guidance may have had differential effects in men 
and women. Further work would be required to explore this.
Although we standardized our results for deprivation in 
sensitivity analyses, we did not adjust for other covariates 
Figure 4. Age and sex standardized incident rate of major cardiovascular disease (per 100 person-years) between April 2006 and March 2017 with 
interruption between April 2011 and March 2012.
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that may influence the risk of hypertension, in particular body 
mass index. However, trends in body mass index over time 
are small (0.2 kg/m2 between 2007 and 2016),28 and results 
accounting for deprivation were similar to our main analyses, 
so further adjustment is unlikely to have altered our results.
Comparisons With Existing Literature
Our finding that the incidence of hypertension has fallen since 
2006 is consistent with observed downward trends in blood 
pressure.29 Considering the aging UK population and that the 
prevalence of hypertension increases with age, our finding 
is also consistent with studies showing that the overall prev-
alence of hypertension is stable.30 The decrease in the inci-
dence of hypertension observed in this study may have been 
driven by an artificially inflated incidence rate shortly after 
the implementation of pay-for-performance indicators in 2004 
in the United Kingdom. However, such an inflation was not 
observed when we repeated our analysis using data from 2003 
onwards (not shown).
Although the change in guidance was associated with 
a change in the rate of out-of-office monitoring, observed 
changes were small in absolute terms. We also observed a de-
cline in office BP measurement after 2011, which would be 
consistent with replacement of at least some of these measure-
ments with out-of-office readings, as recommended. However, 
our findings suggest that the overwhelming majority of BP 
measurement is still recorded as performed in the clinic. This 
may be explained by a failure to implement guideline changes 
properly or from issues in coding. Previous research examin-
ing the impact of other guideline or policy changes have in-
deed shown limited impact on hypertension-related clinical 
practice.16,31 However, repeated UK surveys show that the vast 
majority of UK general practices now have access to home 
and ambulatory BP monitoring, with increases since 2011.32 
Approximately 1 in 5 of all patients are also asked to monitor 
their BP at home.33 This suggests that the low rate of out-of-
office monitoring in this study is more likely to reflect limited 
use of specific coding, rather than limited uptake of guidance. 
This appears to be a systematic issue as results were similar in 
practices where the use of out-of-office BP coding was high. 
This may be due to difficulty in using codes or the fact that 
BP-related pay-for-performance measures depend on clinic 
measurements.34
Implications for Research and Practice
Our results indicate that concerns that the introduction of the 
NICE hypertension guideline in 2011 would result in major 
increases in avoidable cardiovascular events and deaths,10 
appear unfounded, at least in the short-medium term. More re-
cent guidelines in North America35 and Europe36 have taken up 
the UK NICE recommendations. We have found no evidence 
that such continued guidance would materially affect impor-
tant patient outcomes. Further studies, in countries which 
have implemented similar guidance, or restricted to general 
practices which have fully adopted the guideline recommen-
dations, are warranted to confirm our findings.
Our results indicate that the change in guidance was as-
sociated with a relative increase in hypertension diagnoses 
compared with that expected from pre-2011 trends, but further 
research would be required to understand the mechanism 
underpinning this. It is possible that the guideline change 
prompted closer monitoring of patients with borderline clinic 
BP readings who would have subsequently had hypertension 
ruled out (indicating white coat effects) or been diagnosed.
Perspectives
For the diagnosis of hypertension, out-of-office blood pres-
sure monitoring is more accurate8 and cost-effective9 com-
pared with clinic BP monitoring. The results from this study 
suggest that the recommendation of out-of-office monitoring 
for hypertension diagnosis was not associated with observed 
negative consequences. By the end of the observation period, 
around a quarter of all new diagnoses were accompanied by 
recorded out-of-office measurement, but doubt remains re-
garding whether guidance was appropriately implemented or 
whether coding issues masked larger increases in the use of 
out-of-office BP measurement for the diagnosis of hyperten-
sion. The wider implementation of out-of-office monitoring, 
as has been recommended in the recent US, European and 
2019 NICE hypertension guidelines, remains appropriate.
Acknowledgments
The protocol was approved by the Independent Scientific Advisory 
Committee (ISAC) of the Medicines and Healthcare products 
Regulatory Agency (ISAC protocol number 17_239R; available from 
the authors on request). Ethics approval for observational research 
using the Clinical Practice Research Datalink with approval from 
ISAC was granted by a National Research Ethics Service commit-
tee (Trent Multi Research Ethics Committee, REC reference number 
05/MRE04/87). All authors contributed to the study design, funding 
application, and ethical approval. S.L. Lay-Flurrie conducted data 
cleaning and analysis with input from R.J. Stevens and J.P. Sheppard. 
All authors interpreted results. S.L. Lay-Flurrie and R.J. McManus 
drafted the article which all authors then revised. S.L. Lay-Flurrie is 
the guarantor. The corresponding author attests that all listed authors 
meet authorship criteria and that no others meeting the criteria have 
been omitted.
Sources of Funding
This study is funded by the National Institute for Health Research 
(NIHR) School for Primary Care Research (SPCR) (project reference 
388). The views expressed are those of the author(s) and not necessar-
ily those of the NIHR or the Department of Health and Social Care. 
J.P. Sheppard is funded by a Wellcome Trust/Royal Society Sir Henry 
Dale Fellowship (ref: 211182/Z/18/Z) and previously received sup-
port from the NIHR Oxford Collaborations for Leadership in Applied 
Research and Care (CLARHC), and the NIHR School for Primary 
Care Research. C. Mallen is funded by the NIHR Collaborations 
for Leadership in Applied Health Research and Care West Midlands 
and a NIHR Research Professorship in General Practice (NIHR-
RP-2014-04-026). F.D.R. Hobbs acknowledges funding from the 
NIHR School for Primary Care Research, the NIHR CLARHC 
Oxford, the NIHR Oxford Biomedical Research Centre (BRC, 
University Hospitals Trust), and the NIHR Oxford Medtech and In-
Vitro Diagnostics Co-operative (MIC). R.J. McManus received sup-
port from NIHR via Programme Grants for Applied Health research, 
the SPCR, the Oxford CLAHRC, and a Senior Investigator Award. J. 
Mant is an NIHR Senior Investigator. The study sponsors were not 
involved in any aspect of the study including study design, data col-
lection, data analysis, and interpretation of data.
Disclosures
All authors have completed the International Committee of Medical 
Journal Editors uniform disclosure form at www.icmje.org/
D
ow
nloaded from
 http://ahajournals.org by on January 7, 2020
8  Hypertension  February 2020
coi_disclosure.pdf and declare: S.L. Lay-Flurrie reports grants from 
National Institute for Health Research, School for Primary Care 
Research, during the conduct of the study; R.J. McManus reports 
grants from National Institute for Health Research, during the con-
duct of the study and grants from Omron, outside the submitted work; 
and being a member of the 2019 National Institute for Health and 
Care Excellence Hypertension Guideline Committee; J.P. Sheppard 
reports grants from National Institute for Health Research and 
Wellcome Trust, during the conduct of the study; C. Heneghan re-
ports grants from National Institute for Health Research and other ex-
penses from World Health Organization, outside the submitted work, 
and is Editor in chief of the British Medical Journal Evidence-Based 
Medicine and an National Health Service Urgent Care general practi-
tioner. The other authors report no conflicts.
References
 1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, 
Amann M, Anderson HR, Andrews KG, Aryee M et al. A comparative risk 
assessment of burden of disease and injury attributable to 67 risk factors 
and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for 
the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260. 
doi:10.1016/S0140-6736(12)61766-8
 2. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs 
in the prevention of cardiovascular disease: meta-analysis of 147 ran-
domised trials in the context of expectations from prospective epidemio-
logical studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665
 3. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B; 
Guideline Development Group. Management of hypertension: summary 
of NICE guidance. BMJ. 2011;343:d4891. doi: 10.1136/bmj.d4891
 4. Cloutier L, Daskalopoulou SS, Padwal RS, Lamarre-Cliche M, Bolli P, 
McLean D, Milot A, Tobe SW, Tremblay G, McKay DW, et al. A new 
algorithm for the diagnosis of hypertension in Canada. Can J Cardiol. 
2015;31:620–630. doi: 10.1016/j.cjca.2015.02.014
 5. Siu A. Screening for High Blood Pressure in Adults: U.S. Preventive 
Services Task Force Recommendation Statement. Ann Intern Med. 
2015;163:778–786. doi:10.7326/M15-2223
 6. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, 
Imaizumi T, Ishimitsu T, Ito M, et al; Japanese Society of Hypertension 
Committee for Guidelines for the Management of Hypertension. The 
Japanese Society of Hypertension guidelines for the management 
of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390. doi: 
10.1038/hr.2014.20
 7. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, 
Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. 2013 ESH/
ESC guidelines for the management of arterial hypertension: the task 
force for the management of arterial hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology (ESC). 
Eur Heart J. 2013;34:2159–2219. doi: 10.1093/eurheartj/eht151
 8. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, 
Heneghan C, Roberts N, McManus RJ. Relative effectiveness of clinic 
and home blood pressure monitoring compared with ambulatory blood 
pressure monitoring in diagnosis of hypertension: systematic review. 
BMJ. 2011;342:d3621. doi: 10.1136/bmj.d3621
 9. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, 
Hodgkinson J, Mant J, Martin U, Williams B, et al. Cost-effectiveness 
of options for the diagnosis of high blood pressure in primary care: a 
modelling study. Lancet. 2011;378:1219–1230. doi: 10.1016/S0140- 
6736(11)61184-7
 10. Wald DS, Simmonds MC, Morris JK, Rothwell PM, Wald NJ. Cost-
effectiveness of diagnosis of high blood pressure in primary care. Lancet. 
2012;379:709–10; author reply 710. doi: 10.1016/S0140-6736(12)60302-X
 11. Brown MJ, Cruickshank JK, Macdonald TM. Navigating the shoals 
in hypertension: discovery and guidance. BMJ. 2012;344:d8218. doi: 
10.1136/bmj.d8218
 12. Hobbs FDR, Bankhead C, Mukhtar T, Stevens S, Perera-Salazar R, Holt T, 
Salisbury C; National Institute for Health Research School for Primary 
Care Research. Clinical workload in UK primary care: a retrospec-
tive analysis of 100 million consultations in England, 2007-14. Lancet. 
2016;387:2323–2330. doi: 10.1016/S0140-6736(16)00620-6
 13. Maruthappu M, Sood HS, Keogh B. The NHS five year forward view: 
implications for clinicians. BMJ. 2014;349:g6518. doi: 10.1136/bmj.g6518
 14. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, 
Smeeth L. Data resource profile: Clinical Practice Research Datalink 
(CPRD). Int J Epidemiol. 2015;44:827–836. doi: 10.1093/ije/dyv098
 15. Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power cal-
culation for designing interrupted time series analyses of health policy 
interventions. J Clin Epidemiol. 2011;64:1252–1261. doi: 10.1016/j. 
jclinepi.2011.02.007
 16. Sheppard JP, Stevens S, Stevens RJ, Mant J, Martin U, Hobbs FDR,  
McManus RJ. Association of guideline and policy changes with inci-
dence of lifestyle advice and treatment for uncomplicated mild hyperten-
sion in primary care: a longitudinal cohort study in the clinical practice 
research datalink. BMJ Open. 2018;8:e021827. doi:10.1136/bmjopen- 
2018-021827
 17. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regres-
sion for the evaluation of public health interventions: a tutorial. Int J 
Epidemiol. 2017;46:348–355. doi:10.1093/ije/dyw098
 18. Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, 
Bhaskaran K. Impact of statin related media coverage on use of statins: 
interrupted time series analysis with UK primary care data. BMJ. 
2016;353:i3283. doi: 10.1136/bmj.i3283
 19. StataCorp. Stata Statistical Software: Release 14. 2015.
 20. Peng M, Chen G, Kaplan GG, Lix LM, Drummond N, Lucyk K, Garies 
S, Lowerison M, Weibe S, Quan H. Methods of defining hypertension 
in electronic medical records: validation against national survey data. J 
Public Health (Oxf). 2016;38:e392–e399. doi: 10.1093/pubmed/fdv155
 21. Sinnott SJ, Smeeth L, Williamson E, Douglas IJ. Trends for prevalence 
and incidence of resistant hypertension: population based cohort study in 
the UK 1995-2015. BMJ. 2017;358:j3984. doi: 10.1136/bmj.j3984
 22. Herrett E, Shah AD, Boggon R, Denaxas S, Smeeth L, van Staa T, 
Timmis A, Hemingway H. Completeness and diagnostic validity of re-
cording acute myocardial infarction events in primary care, hospital care, 
disease registry, and national mortality records: cohort study. BMJ. 
2013;346:f2350. doi: 10.1136/bmj.f2350
 23. Townsend N, Bhatnagar P, Wilkins E, Wickramasinghe K, Rayner M. 
Cardiovascular Disease Statistics 2015. British Heart Foundation: 
London; 2015.
 24. NHS Digital. General and Personal Medical Services, England 2006-
2016. London, UK: NHS Digital; 2017.
 25. Watkins J, Wulaningsih W, Da Zhou C, Marshall DC, Sylianteng GDC, 
Dela Rosa PG, Miguel VA, Raine R, King LP, Maruthappu M. Effects of health 
and social care spending constraints on mortality in England: a time trend 
analysis. BMJ Open. 2017;7:e017722. doi: 10.1136/bmjopen-2017-017722
 26. Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pres-
sure target, time to intensification, and time to follow-up in treatment 
of hypertension: population based retrospective cohort study. BMJ. 
2015;350:h158. doi: 10.1136/bmj.h158
 27. Sheppard JP, Fletcher B, Gill P, Martin U, Roberts N, McManus RJ. 
Predictors of the home-clinic blood pressure difference: a systematic 
review and meta-analysis. Am J Hypertens. 2016;29:614–625. doi: 
10.1093/ajh/hpv157
 28. NatCen Social Research. Health Survey for England 2016: Adult Health 
Trends. London, UK: NHS Digital; 2017.
 29. NCD Risk Factor Collaboration. Worldwide trends in blood pressure 
from 1975 to 2015: a pooled analysis of 1479 population-based meas-
urement studies with 19·1 million participants. Lancet. 2017;389:37–55. 
doi:10.1016/S0140-6736(16)31919-5
 30. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management 
in England: a serial cross-sectional study from 1994 to 2011. Lancet. 
2014;383:1912–1919. doi:10.1016/S0140-6736(14)60688-7
 31. Serumaga B, Ross-Degnan D, Avery AJ, Elliott RA, Majumdar SR, 
Zhang F, Soumerai SB. Effect of pay for performance on the management 
and outcomes of hypertension in the United Kingdom: interrupted time 
series study. BMJ. 2011;342:d108. doi: 10.1136/bmj.d108
 32. Mejzner N, Clark CE, Smith LF, Campbell JL. Trends in the diag-
nosis and management of hypertension: repeated primary care survey 
in South West England. Br J Gen Pract. 2017;67:e306–e313. doi: 
10.3399/bjgp17X690461
 33. Stevens SL, McManus RJ, Stevens RJ. Current practice of usual clinic 
blood pressure measurement in people with and without diabetes: a survey 
and prospective ‘mystery shopper’ study in UK primary care. BMJ Open. 
2018;8:e020589. doi: 10.1136/bmjopen-2017-020589
 34. Primary Care Domain Specification Development Service (NHS Digital). 
Business rules for Quality and Outcomes Framework (QOF) 2017/18. 
Hypertension. 2017.
 35. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, 
Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones 
DW, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/
NMA/PCNA guideline for the prevention, detection, evaluation, and 
D
ow
nloaded from
 http://ahajournals.org by on January 7, 2020
Lay-Flurrie et al  Impact of Hypertension Guideline Change in the United Kingdom  9
management of high blood pressure in adults: a report of the American 
College of Cardiology/American Heart Association task force on clin-
ical practice guidelines. J Am Coll Cardiol. 2018;71:e127–e248. doi: 
10.1016/j.jacc.2017.11.006
 36. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, 
Clement DL, Coca A, de Simone G, Dominiczak A, et al. 2018 ESC/ESH 
guidelines for the management of arterial hypertension. Eur Heart J. 
2018;39:3021–3104. doi:10.1093/eurheartj/ehy339
What Is New?
•	National guidelines in the United Kingdom recommended the use of out-
of-office monitoring for hypertension diagnosis in 2011, but it was sug-
gested this may increase rates of cardiovascular disease. This study is 
the first to formally evaluate the impact of these guideline changes on 
clinical outcomes at the population level.
What is Relevant?
•	Our study shows that changes to guidelines in 2011 were associated 
with a leveling off of downward trends in the incidence of hypertension 
and increases in the use of out-of-office monitoring. Changes were not 
associated with an increase in cardiovascular events, at least in the 
short-medium term.
Summary
Based on current evidence, the continued recommendation of out-
of-office monitoring for hypertension diagnosis is unlikely to affect 
hard patient outcomes.
Novelty and Significance
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